Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terminalia macroptera aqueous extract (AETM) is a botanical extract derived from the *Terminalia macroptera* tree, a medicinal plant native to West Africa. It is being investigated for its neuroprotective potential, particularly in the treatment of Parkinson's disease. The extract exhibits significant antioxidant and anti-inflammatory properties, which are thought to mediate its therapeutic effects. In preclinical models, AETM has demonstrated the ability to restore dopamine levels, enhance motor performance, and preserve the integrity of dopaminergic neurons in the substantia nigra. Its mechanism involves the restoration of antioxidant enzyme activities (such as superoxide dismutase and catalase) and the reduction of pro-inflammatory cytokines, including interleukin-1β and tumor necrosis factor-α.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Terminalia macroptera aqueous extract.